Boao Evergrande International Hospital and Boston Scientific Establish Liver Cancer Radioembolization Center Featuring TheraSphere Y-90 Glass Microspheres

Shanghai, November 6, 2019 /PRNewswire/ -- Boao Evergrande International Hospital and Boston Scientific Corporation (NYSE: BSX) signed a cooperation agreement at the second China International Import Expo held in Shanghai, announcing the introduction of TheraSphere, the world's first radioactive glass microspheres.Y-90Radioactive Seeds: Establishing a Liver Cancer Interventional Radiology Center with This as the Primary Treatment Modality.

On that day, Yang Yi, President of Boao Evergrande International Hospital, and Da Bo, Vice President of Boston Scientific, signed the cooperation agreement on behalf of both parties. Shen Xiaoming, Deputy Secretary of the Hainan Provincial Committee of the Communist Party of China and Governor of Hainan Province; Ren Guosheng, Chief Medical Officer of Evergrande Health Group; and Zhang Jun, Global Vice President of Boston Scientific and General Manager of Greater China, attended the ceremony and witnessed the signing.

AsAs a global leader in medical technology, Boston Scientific Corporation continues to pioneer innovations in interventional oncology. Its world-first radioactive glass microspheres—TheraSphere Y-90 radiation particles—offer new hope for patients with liver cancer. Since the establishment of the Boao Lecheng International Medical Tourism Pilot Zone in 2013, and leveraging the special access policies under the “National Nine Articles,” Boao Evergrande International Hospital has been committed to introducing advanced international medical technologies while providing high-quality diagnostic and therapeutic services for cancer patients.

By jointly establishing a Liver Cancer Interventional Radiology Treatment Center, both parties will integrate their strengths in talent resources, new medical technologies, novel drugs and devices, and nuclear medicine. They will actively pursue comprehensive collaboration in the clinical application of radiopharmaceuticals and new interventional therapies, talent training, and translation of research outcomes into practice, thereby further supporting the Pilot Zone in achieving its 2025 goal of “triple synchronization” with international advanced standards in medical technology, equipment, and pharmaceuticals.

Yang Yi, President of Boao Evergrande International Hospital, stated that through this collaboration, the hospital will further align with international standards in the field of oncology treatment, provide Chinese patients with superior treatment options, and boost the rapid development of Hainan’s healthcare industry.

Zhang Jun, Global Vice President of Boston Scientific and General Manager of Greater China, also stated that Boston Scientific will join hands with Boao Evergrande International Hospital to jointly promote the upgrading and development of China’s healthcare industry, making more breakthrough medical solutions accessible to patients in China.